Financial reports
10-K
2023 FY
Annual report
15 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
12 Apr 23
NT 10-K
Notice of late annual filing
31 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
Current reports
8-K
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
12 Apr 24
8-K
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
11 Apr 24
8-K
Regulation FD Disclosure
23 Jan 24
8-K
Oncocyte Reports Third Quarter 2023 Financial Results
9 Nov 23
8-K/A
Changes in Registrant's Certifying Accountant
10 Oct 23
8-K
Changes in Registrant's Certifying Accountant
5 Oct 23
8-K
Entry into a Material Definitive Agreement
20 Sep 23
8-K
Other Events
28 Aug 23
8-K
Oncocyte Reports Second Quarter 2023 Financial Results
10 Aug 23
8-K
ONCOCYTE ANNOUNCES 1-for-20 reverse stock split
24 Jul 23
Registration and prospectus
D
$15.81 mm in equity / options / securities to be acquired, sold $15.81 mm, 21 investors
24 Apr 24
424B5
Prospectus supplement for primary offering
5 Apr 23
424B5
Prospectus supplement for primary offering
18 Apr 22
424B5
Prospectus supplement for primary offering
15 Apr 22
424B5
Prospectus supplement for primary offering
13 Apr 22
424B3
Prospectus supplement
29 Jul 21
S-3
Shelf registration
14 Jul 21
S-8
Registration of securities for employees
7 Jul 21
424B5
Prospectus supplement for primary offering
14 Jun 21
S-3
Shelf registration
28 May 21
Proxies
DEFA14A
Additional proxy soliciting materials
21 Jul 23
DEF 14A
Definitive proxy
10 Jul 23
PRE 14A
Preliminary proxy
30 Jun 23
DEFR14A
Revised proxy
22 May 23
DEF 14A
Definitive proxy
19 May 23
DEF 14A
Definitive proxy
8 Jun 22
PRE 14A
Preliminary proxy
26 May 22
DEFA14A
Additional proxy soliciting materials
21 May 21
DEF 14A
Definitive proxy
21 May 21
PRE 14A
Preliminary proxy
10 May 21
Other
EFFECT
Notice of effectiveness
30 Jul 21
CORRESP
Correspondence with SEC
26 Jul 21
UPLOAD
Letter from SEC
21 Jul 21
EFFECT
Notice of effectiveness
9 Jun 21
CORRESP
Correspondence with SEC
4 Jun 21
UPLOAD
Letter from SEC
3 Jun 21
CORRESP
Correspondence with SEC
28 May 21
CERT
Certification of approval for exchange listing
5 Mar 21
EFFECT
Notice of effectiveness
21 Aug 20
CORRESP
Correspondence with SEC
17 Aug 20
Ownership
SC 13G
BIO-RAD LABORATORIES, INC.
22 Apr 24
SC 13D/A
BROADWOOD PARTNERS, L.P.
15 Apr 24
4
NEAL C BRADSHER
15 Apr 24
4
Josh Riggs
15 Apr 24
4
Andrew Arno
15 Apr 24
SC 13G/A
PURA VIDA INVESTMENTS, LLC
14 Feb 24
SC 13G/A
AWM Investment Company, Inc.
14 Feb 24
4
James Yang Liu
12 Oct 23
4
Josh Riggs
17 Aug 23
4
John Peter Gutfreund
3 Jul 23